¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"peripheral nervous system agents"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • genital system
    »ý½Ä°èÅë, »ý½Ä°è, »ý½Ä±â°è
  • genitourinary system
    ºñ´¢»ý½Ä°èÅë, ºñ´¢»ý½Ä°è
  • Haversian system
    ÇϹö½º°è
  • health care delivery system
    ÀÇ·áÀü´Þü°è
  • hypophyseal portal system
    ³úÇϼöü¹®¸Æ°è
  • health care system
    º¸°ÇÀÇ·áü°è
  • health information system
    º¸°ÇÁ¤º¸Ã¼°è
  • hematopoietic system
    Ç÷±¸Çü¼º°èÅë, Á¶Ç÷°è
  • hospital information system
    º´¿øÁ¤º¸Ã¼°è
  • immobilization system
    °íÁ¤¹æ½Ä
  • immune system
    ¸é¿ªÃ¼°è
  • impulse conducting system
    ½ÉÀåÈïºÐÀüµµ°èÅë
  • information system
    Á¤º¸Ã¼°è
  • integumentary system
    ÇǺΰèÅë, ¿ÜÇǰè
  • International System of Units
    ±¹Á¦´ÜÀ§°è
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • countercurrent system
    ¿ª·ù°è
  • countercurrent exchanger system
    ¿ª·ù±³È¯°è
  • countercurrent multiplier system
    ¿ª·ùÁõÆø°è
  • culture system
    ¹è¾ç½Ã½ºÅÛ
  • digestive system
    ¼ÒÈ­°èÅë
  • display system
    Ç¥½ÃÀåÄ¡
  • distric health system
    Áö¿ªº¸°Çü°è
  • drug delivery system
    ¾à¹°Àü´Þü°è
  • dual foil system
    ÀÌÁß¹Ú¸·±¸Á¶
  • dynamic system
    µ¿Àû°èÅë
  • ecological system
    »ýŰè
  • electro transfer system
    ÀüÀÚÀü´Þ°è, ÀüÀÚ¿î¹Ýü
  • electro-optical system
    Àü±â±¤Çкм®°è
  • endocrine system
    ³»ºÐºñ°èÅë
  • exhaust system
    ¹èÃâÀåÄ¡, ¹è±â½Äȸ·Î
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • genital system
    »ý½Ä±â°è(ßæãÖÐïͧ)
  • genitourinary system
    ºñ´¢»ý½Ä±â°èÅë(ù²èñßæãÖÐïͧ÷Ö).
  • genitourinary system
    ºñ´¢»ý½Ä±â°èÅë(ù²èñßæãÖÐïͧ÷Ö).
  • global budget system
    ÃѾ׿¹»êÁ¦, ÃѾװè¾àÁ¦.
  • guarantee system
    º¸ÁõÁ¦µµ(ËÓ̡̡̬).
  • h2o2-myeloperxidase-halide system
    °ú»êÈ­¼ö¼Ò-°ñ¼ö°ú»êÈ­È¿¼Ò-ÇÒ·Î°Õ °èÅë
  • hamatopoietic system
    Á¶Ç÷±â°ü(ðãúìÐïί)
  • health care delivery system
    ÀÇ·áÀü´ÞÁ¦µµ(ËöËíËøËÀ̡̬).
  • health care system
    º¸°ÇÀÇ·áü°è.
  • health information system
    º¸°ÇÁ¤º¸Ã¼°è.
  • heterogeneous system
    ºÒ±ÕÀϰè, ºÒ±ÕÁú°è.
  • hexagonal system
    À°¹æ°áÁ¤°è.
  • homogeneous system
    ±ÕÁú°è, ±ÕÀϰè.
  • hospital information system
    º´¿øÁ¤º¸Ã¼°è.
  • hydrophilic system
    Ä£¼ö°è(öÑâ©Í§).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • peripheral aneurysm
    ¸»Ãʵ¿¸Æ·ù(ØÇôþÔÑØæ×»)
  • peripheral anosmia
    ¸»ÃÊ(¼º) ¹«Èİ¢Áõ
  • peripheral anterior synechia
    ÁÖº¯È«Ã¤¾ÕÀ¯Âø
  • peripheral blood
    ¸»ÃÊÇ÷(ØÇ úì).
  • peripheral cataract
    ÁÖº¯¹é³»Àå
  • peripheral chemoreceptor
    ¸»ÃÊÈ­Çмö¿ëü(ØÇ ûùùÊáôé»ô÷).
  • peripheral chorioretinal degeneration
    ÁÖº¯¸Æ¶ô¸Á¸·º¯¼º
  • peripheral circulation
    ¸»ÃʼøÈ¯(ØÇ âàü»).
  • peripheral circulatory disturbance
    ¸»ÃʼøÈ¯Àå¾Ö(¡­î¡äô).
  • peripheral corneal degeneration
    ÁÖº¯°¢¸·º¯¼º
  • peripheral corneal ectasia
    ÁÖº¯°¢¸·È®ÀåÁõ
  • peripheral cyanosis
    ¸»ÃÊû»öÁõ(¡­ôìßäñø).
  • peripheral cyanosis
    ¸»ÃÊû»öÁõ(ØÇôþôìßäñø)
  • peripheral cystoid degeneration
    ÁÖº¯³¶Æ÷º¯¼º
  • peripheral dendritic process
    ¸»Ãʰ¡Áöµ¹±â¼º µ¹±â, ¸»Ãʼö»óµ¹±â¼º µ¹±â(¡­ â§ßÒÔÍÑÃàõÔÍÑÃ).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
NTV Nervous Tissue Vaccine; ½Å°æ Á¶Á÷ ¹é½Å
ARNMD Association for Research in Nervous and Mental Diseases
CNE chief nurse executive; chronic nervous exhaustion; concentric needle electrode
CNES chronic nervous exhaustion syndrome
ner nervous
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
auto-PBSCT Autologous peripheral blood stem cell transplantation
HPBL Human peripheral blood lymphocytes
hu-PBL Human peripheral blood lymphocytes
HPBM Human peripheral blood monocytes
HPBMC human peripheral blood mononuclear cell
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • achromatic system
    ¹«»ö°è
  • aerospace life support system
    ¿ìÁÖ¿ë »ý¸í À¯Áö ½Ã½ºÅÛ
  • affecting multiple system
    ´Ù¹ß¼º °èÅëÀ» ħ¹üÇÑ
  • affectional system
    Á¤µ¿ ü°è
  • afferent system
    ±¸½É ½Å°æ°è
  • alloy system
    Çձݰè
  • analgesia system
    ÁøÅë°è
    ÁßÃß ½Å°æ°è°¡ °¡Áø µ¿ÅëÀ» ÅëÁ¦ÇÏ´Â ÀÏ·ÃÀÇ ½Å°æ Á¶Á÷. ÁÖ·Î ½Å°æ ¼¼Æ÷¿¡¼­ o
  • aqueous system
    ¼ö¼º°è
  • ArF system emission spectra
    ArF°è ¹æÃâ ½ºÆåÆ®·³
  • ascending projection system
    »óÇà Åõ»ç°è
  • autologous blood recovery system
    ÀÚ°¡ Ç÷¾× ȸº¹ ÀåÄ¡
  • bicarbonate buffer system
    Áßź»ê¿° ¿ÏÃæ°è
  • biliary system
    ´ã³¶°è
  • biomedical classification system
    »ýÀÇÇÐÀû ºÐ·ù ü°è
  • breathing system
    È£Èí ÀåÄ¡
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
abortifacient agents Chemical substances that interrupt pregnancy after implantation.
(12 Dec 1998)
abortifacient agents, non-steroidal Non-steroidal chemical compounds with abortifacient activity.
(12 Dec 1998)
abortifacient agents, steroidal Steroidal compounds with abortifacient activity.
(12 Dec 1998)
adrenergic agents Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters.
(12 Dec 1998)
alkylating agents Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agent, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases.
(12 Dec 1998)
anti-allergic agents Agents that are used to treat allergic reactions. most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells.
(12 Dec 1998)
anti-anxiety agents Agents that alleviate anxiety, tension, and neurotic symptoms, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. Some are also effective as anticonvulsants, muscle relaxants, or anaesthesia adjuvants. Adrenergic beta-antagonists are commonly used in the symptomatic treatment of anxiety but are not included here.
Substances with a benzodiazepine ring structure widely used to treat anxiety and neuroses. Drugs in this class also generally have sedative or weak hypnotic properties and may be effective as muscle relaxants, anticonvulsants, and anaesthesia adjuvants.
(12 Dec 1998)
anti-arrhythmia agents Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.
(12 Dec 1998)
anti-asthmatic agents Drugs that are used to treat asthma.
(12 Dec 1998)
anticarcinogenic agents Agents that reduce the frequency or rate of spontaneous or induced tumours independently of the mechanism involved. They differ from antineoplastic agent in that they prevent neoplasms from forming. The anticarcinogenic substances can be divided into three categories. The first consists of compounds that prevent the formation of carcinogens from precursor substances. The second group consists of "blocking agents" which inhibit carcinogenesis by preventing carcinogenic agents from reaching or reacting with critical target sites in the tissues. The third group is the "suppressor agents" which act by suppression of expression of neoplasia in cells previously exposed to carcinogens that would otherwise cause neoplasms.
(12 Dec 1998)
anticestodal agents Agents used to treat tapeworm infestations in man or animals.
(12 Dec 1998)
anticholesteraemic agents Substances that promote a reduction of blood cholesterol levels.
(12 Dec 1998)
anti-coagulant agents Medications, like heparin, used as blood-thinners to prevent blood clots and to maintain open blood vesssels.
(12 Dec 1998)
antidepressive agents Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several monoamine oxidase inhibitors are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (antidepressive agents, tricyclic) also appear to act through brain catecholamine systems. A third group (antidepressive agents, second-generation) is a diverse group of drugs including some that act specifically on serotonergic systems.
(12 Dec 1998)
antidepressive agents, second-generation A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • metric system
    ¹ÌÅ͹ý
  • metric system
    ¹ÌÅ͹ý(µµ·®Çü º¾¿¡¼­ ´ÜÀ§¸¦ meter,liter,gramÀ¸·Î ÇÔ)
  • mountain system
    »ê°è
  • natural system
    ÀÚ¿¬ºÐ·ù(natural classification)
  • numbering system
    ¼ýÀÚ¸¦ »ç¿ëÇÏ¿© Ŭ·¹À̸¦ ³ªÅ¸³»´Â ¹æ½Ä(°¢ ¼±¼öÀÇ À§Ä¡,¼±¼ö°£ÀÇ Áö¿ª¿¡ ¹øÈ£¸¦ ºÙÀÓ)
  • oneline real time system
    Á÷°á ½Ç½Ã°£ ó¸® ¹æ½Ä
  • periodic system
    ÁÖ±â°è;ÁÖ±âÀ²¿¡ µû¸¥ ¿ø¼Ò ü°è
  • point system
    Æ÷ÀÎÆ®½Ä;¸ÍÀοëÀÇ Á¡ÀÚ ¹æ½Ä;ÇÐÁ¡Á¦;¿îÀü À§¹ÝÀÇ Á¡¼öÁ¦
  • premium system
    »ó¿© Á¦µµ(½Ã°£±ÞÀ» Á¤ÇÏ°í ¼ÒÁ¤ ½Ã°£º¸´Ù »¡¸® µÇ¸é ÇÒÁõ ±Þ¿©¸¦ ÁÜ)
  • private-wire system
    »ç¼³ ÀüÈ­(ÅÚ·º½º) ȸ¼±¸Á
  • profit system
    =FREE ENTERPRIZE
  • proportional reserve system
    (Á¤È­ Áغñ¿Í ÁöÆó ¹ßÇà°íÀÇ) ºñ·Ê ÁغñÁ¦
  • protective system
    º¸È£ ¹«¿ª Á¦µµ
  • public address system
    (°­´çµîÀÇ)È®¼º ÀåÄ¡
  • publicaddress system
    È®¼º ÀåÄ¡
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á